Although it’s a long way from the president’s desk, the Tax Cut and Jobs Act of 2017 contains plenty of good news for the life sciences industry and its marketing partners.
Five things for pharma marketers to know: Tuesday, October 3, 2017
The FDA updates Gilenya’s label over definite case of PML; generic drug companies are consolidating for negotiating power; the FDA revises guidance on DTC risk information
Five things for pharma marketers to know: Friday, May 1
Nexium tops the list of Medicare’s spending on brand drugs; Gilead Sciences doubles its first-quarter profit; Pfizer reportedly wants to buy a rare-disease drug company
FDA may tighten drug environmental rules
April 30, 2015
3:00 pm
Draft guidance would require applications for drugs that interact with or include hormones to include environmental impact assessments.
Five things for pharma marketers to know: Thursday, March 12
The SEC said some company drug prices can be made public, 23andMe launched an R&D division, and Public Citizen is asking the FDA to withdraw a proposal it says will undermine drug safety information.
Loading...
MM+M Transform: The Patient, Provider and Payer Engagement Matrix